Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC raised its holdings in Incyte Corporation (NASDAQ:INCY) by 627.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 186,790 shares of the biopharmaceutical company’s stock after buying an additional 161,124 shares during the quarter. SG Americas Securities LLC owned about 0.10% of Incyte worth $18,449,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Bank of Nova Scotia increased its position in shares of Incyte by 0.7% during the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock valued at $1,160,000 after purchasing an additional 124 shares during the period. MAI Capital Management lifted its position in Incyte by 19.9% in the second quarter. MAI Capital Management now owns 754 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 125 shares during the period. Atlantic Edge Private Wealth Management LLC boosted its stake in Incyte by 0.9% during the third quarter. Atlantic Edge Private Wealth Management LLC now owns 14,556 shares of the biopharmaceutical company’s stock worth $1,235,000 after buying an additional 125 shares in the last quarter. Perbak Capital Partners LLP boosted its stake in Incyte by 2.5% during the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock worth $449,000 after buying an additional 129 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its holdings in Incyte by 0.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 19,912 shares of the biopharmaceutical company’s stock valued at $1,356,000 after buying an additional 158 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling at Incyte

In other news, EVP Mohamed Khairie Issa sold 10,856 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the transaction, the executive vice president owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pablo J. Cagnoni sold 18,667 shares of Incyte stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $94.24, for a total transaction of $1,759,178.08. Following the sale, the insider directly owned 234,800 shares of the company’s stock, valued at $22,127,552. This represents a 7.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 17.80% of the stock is currently owned by company insiders.

Incyte Price Performance

Incyte stock opened at $90.30 on Friday. The business’s fifty day moving average is $98.98 and its two-hundred day moving average is $96.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.32. The firm has a market cap of $17.97 billion, a P/E ratio of 14.09, a P/E/G ratio of 0.73 and a beta of 0.84. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $112.29.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). Incyte had a return on equity of 26.34% and a net margin of 25.03%.The company had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.35 billion. During the same period in the prior year, the firm posted $1.43 earnings per share. The company’s revenue was up 27.8% on a year-over-year basis. Equities research analysts forecast that Incyte Corporation will post 4.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on INCY shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $90.00 target price on shares of Incyte in a research report on Thursday, January 8th. Barclays reissued an “overweight” rating on shares of Incyte in a research report on Tuesday. Mizuho set a $121.00 price objective on Incyte and gave the company an “outperform” rating in a report on Monday, December 8th. Wall Street Zen lowered Incyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Stifel Nicolaus increased their target price on Incyte from $119.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Nine investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Incyte presently has an average rating of “Hold” and a consensus price target of $104.89.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.